Talazoparib (BMN 673)

For research use only.

Catalog No.S7048 Synonyms: LT-673

131 publications

Talazoparib (BMN 673) Chemical Structure

CAS No. 1207456-01-6

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 489 In stock
USD 470 In stock
USD 1417 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Talazoparib (BMN 673) has been cited by 131 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
Features Most potent and selective PARPi reported thus far.
Targets
PARP1 [1]
(Cell-free assay)
0.57 nM
In vitro

BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. [1] In cultured human cancer cells, BMN 673 also significantly enhances the cytotoxic efficacy of both Temozolomide and SN-38. Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BR5FVB1-Akt MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[3Z3VJOC5zLUGwNEBvVQ>? M2nhR|I1NzR6L{eyJIg> Ml;QbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= NGnx[mQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0O|Y6Pyd-Mk[wOFc3QTd:L3G+
BR5FVB1-Akt MXPBdI9xfG:|aYOgRZN{[Xl? MmLvNE4yNTFyMDDuUS=> M{fkeFczKGh? M{TLNIlv\HWlZYOgZZBweHSxc3nz M2nKWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES3Olk4Lz5{NkC0O|Y6PzxxYU6=
Capan-1 NVK4XHFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33ZS2lEPTB;MU[uNQKBkcLz4pEJOU416oDLwsXNxsA> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NEW5NEc,OjV6NkS1PVA9N2F-
MIA PaCa-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITPNo1KSzVyPUW4MlI{6oDLwsJihKk5NjIkgJpCuW3DqA>? NHfqNoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OFU6OCd-MkW4OlQ2QTB:L3G+
RD MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRThwNzDuUS=> M3rMV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
Rh41 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRThwMTDuUS=> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
Rh18 M1iw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwOTDuUS=> M1PsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
Rh30 NV:2TJdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jnXGlEPTB;M{GuNUBvVQ>? M{[zblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
BT-12 MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[2TWM2OD8kgJmxMFAxOCCwTR?= Mof3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-266 M2nQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33wWWlEPTB-4pEJNUwxODBibl2= NVrNPGJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
TC-71 M33oSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jQd2lEPTB;Mz63JI5O NEG2[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
CHLA-9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRThwMjDuUS=> M37oN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
CHLA-10 NXSyXHV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HUbGlEPTB;NkeuPEBvVQ>? MnnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
CHLA-258 NXXpRWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi1fZpKSzVyPUSuOkBvVQ>? M3nxelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
SJ-GBM2 NEXk[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrJTWM2OD1zNj6yJI5O NXnxbXVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
NB-1643 NWDlNm9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXnVI9VUUN3ME2xPE41KG6P MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
NB-EBc1 M{D3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJ3Lkigcm0> M1XtflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
CHLA-90 M4O1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRuLCiUGsNFAxKG6P NWP5OJRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
CHLA-136 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfNd5FKSzVyPUG0MlIhdk1? MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
NALM-6 NUH1[ld7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn62TWM2OD12OTDuUS=> MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
COG-LL-317 NIHFOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrtTWM2OD17LkSgcm0> M1HnW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
RS4;11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7JTWM2OD13Mj62JI5O MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4M{WzPUc,OjV{NkO1N|k9N2F-
MOLT-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:wTWM2OD1zNj62JI5O NIPrXJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
CCRF-CEM M1rpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnqSWJVUUN3ME22PVcvOyCwTR?= NX3tbVFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlM2OzlpPkK1NlY{PTN7PD;hQi=>
Kasumi-1 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTd6Nj6yJI5O M4PlSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zOVM6Lz5{NUK2N|U{QTxxYU6=
Karpas-299 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXQTWM2OD15NT63JI5O MonNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkO1N|koRjJ3Mk[zOVM6RC:jPh?=
Ramos-RA1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHTTWM2OD14OD6zJI5O NILMZo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|U{QSd-MkWyOlM2Ozl:L3G+
DT40 NYrSfIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDvcoNKSzVyPUSgcm0> M4nhWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W2PFE{Lz5{NEO1OlgyOzxxYU6=
DU145 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFzIH7N MnTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
H209 NYLk[nJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq4PHBKSzVyPUGuO{BvVQ>? MlrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
H1048 NFzCfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDnTWM2OD1{LkKgcm0> NGDmb4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
H524 M{HJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwMTDuUS=> NWPwXWtlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H1930 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnKSJVPUUN3ME20MlEhdk1? MkXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
H69 NYHWdZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDETWM2OD13LkKgcm0> NYrOeIM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H2081 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSyOpZCUUN3ME22MlMhdk1? NYSxZ5F2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwO|c{PTBpPkK0NFc4OzVyPD;hQi=>
H2107 NY\YOlNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\RWXVKSzVyPUeuN{BvVQ>? NEfVeYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
H1092 NFfacJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP6TWM2OD16Lkmgcm0> MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
DMS-79 NVy4SJA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTMTWM2OD17LkOgcm0> NI\HbYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC3O|M2OCd-MkSwO|c{PTB:L3G+
H446 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;rRWlEPTB;MUOgcm0> MnzKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyN{ezOVAoRjJ2MEe3N|UxRC:jPh?=
COR-L279 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn25TWM2OD1zNTDuUS=> M2PEd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEe3N|UxLz5{NEC3O|M2ODxxYU6=
LoVo MVHGeY5kfGmxbjDhd5NigQ>? NHTXSVc{OCCvaX7z MUPFR|UxKD1iMD6wNFI2KM7:TR?= NXjKfllVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlExQTZpPkK1O|YyODl4PD;hQi=>
MX1 M4jxU2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYLFR|UxKD1iMD6wNFA{KM7:TR?= Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
LoVo MXjGeY5kfGmxbjDhd5NigQ>? MknMN|AhdWmwcx?= M4XNc2VEPTBiPTCwMlAxOjVzIN88US=> M1nMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
LoVo NIrVc3BEgXSxdH;4bYNqfHliYYPzZZk> MYqwMlQhfU1? MonkOUBl[Xm| NXz1bFFrT0l3MDC9JFAvODB2IN88US=> NWG3eoZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
Capan1 MlfHR5l1d3SxeHnjbZR6KGG|c3H5 MnO1SWM2OCB;IECuNFA2KM7:TR?= M2\EWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MRC5 NEixT2dEgXSxdH;4bYNqfHliYYPzZZk> M1P6Z2VEPTBiPTCwMlMyKM7:TR?= NHHGfW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MX1 Mkf0SpVv[3Srb36gZZN{[Xl? NWXnXXNuOSCvZz;r[y=> MnriNkAtQCCjbnSgNlQhcHK| NEHreYdF\WO{ZXHz[UBqdiCSQWKgcIV3\WxiaX6gZZRpgW2rYzDueU9vfSCvb4Xz[UB5\W6xZ4Lh[pRm\CC5aYToJIh2dWGwIF3YNUBk\WyuczDheEAyKG2pL3vnMEBxdyCjZH3pcol{fGW{ZXSgZZMhe2mwZ3zlJIRwe2VibXXhd5Vz\WRiYX\0[ZIhOiBuODDhcoQhOjRiaILzJIJ6KEWOSWPB M{f4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MX1 NEf4bm9CdnSrdIXtc5Ih[XO|YYm= MWewMlM{KG2pL3vn MWqyPEBl[Xm| MXjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDCVmNCOSCmZX\pZ4lmdnRiaIXtZY4hVVhzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpUwdnVibX;1d4Uh[XRiMD6zN{Bu\y:tZzygdI8heWRiYXTtbY5qe3SncnXkJIZweiB{ODDkZZl{ MlvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MX1 NH31cZBCdnSrdIXtc5Ih[XO|YYm= M{XHWFAvOTZ3IH3nM4to MXKyPEBl[Xm| MXLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDCVmNCOSCmZX\pZ4lmdnRiaIXtZY4hVVhzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpUwdnVibX;1d4Uh[XO|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6xOlUhdWdxa3esJJBwKGGmbXnubZN1\XKnZDD0e4lk\SCjIHThfUBnd3JiMkig[IF6ew>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MX1 MoHtSpVv[3Srb36gZZN{[Xl? M2TEWVAvOzNibXevb4c> M{XLUnBwfGWwdHnheIlwdiCxZjDjZZJjd3CuYYTpck1qdmS3Y3XkJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIH;mJGJTS0FzIHTl[olkcWWwdDDoeY1idiCPWEGgZ4VtdHNieHXuc4dz[W[2ZXSgbY4h[XSqeX3pZ{BvfS:wdTDtc5V{\SCjdDCwMlM{KG2pL3vnJJBwKGGwZDDhcolu[Wy|IIfldoUhfHKnYYTl[EB4cXSqIHPhdoJweGyjdHnuJIF1KDN3IH3nM4toNCCrcDDvckBl[XliMR?= M3PmWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
MDA-MB-436 NUfGUpZMSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MkjrO{Bl[Xm| NEXabpFKSzVyIE2gNE4xODB5IN88US=> M4L0cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkmyPVE3Lz5{OE[5NlkyPjxxYU6=
Capan1 MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MkfkO{Bl[Xm| NIH6S3BKSzVyIE2gNE4xODF6IN88US=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ7MkmxOkc,Ojh4OUK5NVY9N2F-
VC8 NWLKN2NwS3m2b4TvfIlkcXS7IHHzd4F6 NIrYZ5g{KGSjeYO= NYrxNolFUUN3MDC9JFAvODB2MjFOwG0> Mlv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OUK5NVYoRjJ6NkmyPVE3RC:jPh?=
V79 NFnOSXBEgXSxdH;4bYNqfHliYYPzZZk> Mo\PN{Bl[Xm| M4PiO2lEPTBiPTC1MlAyOTRizszN NEDmfXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[5NlkyPid-Mki2PVI6OTZ:L3G+
Capan1 NUL5RoRsTnWwY4Tpc44h[XO|YYm= NE\2UYExNjFidV2= NGGxc|c1KGi{cx?= NIr4NZpKdmirYnn0bY9vKG:oIGDBVnAyKGmwIFLSR2EzKGSnZnnjbYVvfCCqdX3hckBE[XCjbkGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hWEGUUEGtSG5CKHS{YYDwbY5oKGG2IECuNUB2VSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NWe0R3FvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PVI6OTZpPkK4OlkzQTF4PD;hQi=>
MDA-MB-436 NUfFcpVwTnWwY4Tpc44h[XO|YYm= MX[xJJVO NE\wWJM1KGi{cx?= M2O0UGlvcGmkaYTpc44hd2ZiUFHSVFEhcW5iQmLDRVEh\GWoaXPp[Y51KGi3bXHuJG1FSS2PQj20N|Yh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iUFHSVFEuTE6DIITyZZBxcW6pIHH0JFEhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M4HYUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkmyPVE3Lz5{OE[5NlkyPjxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved-PARP / cleaved-caspase3 / γ-H2AX; 

PubMed: 29158830     


Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in W0069 cells.

pKAP1 / pChk2 / pChk1; 

PubMed: 28947502     


Western blot images (representative from 3 independent experiments) showing the impact of a 24 hour pre-treatment with TAL ± TMZ on DNA damage signaling in U251 (MGMT-low) and T98G (MGMT-high) cells. 

PD-L1; 

PubMed: 28167507     


MDA-MDA-MB-231 and BT549 cells were treated with 10 μM olaparib or 10 nM talazoparib for 24 hours, and subjected to immunoblotting with the indicated antibodies. PD-L1 knockout (K/O) cells were included as a negative control. 

p-ATM; 

PubMed: 30472087     


Western blot analysis of the DNA damage sensors ATM, p-ATM (Ser1981), CHK1, p-CHK1 (Ser317), CHK2 and p-CHK2 (Thr68) in MV4-11 and HL-60 cells. GAPDH served as a loading control.

29158830 28947502 28167507 30472087
Growth inhibition assay
Cell viability; 

PubMed: 29158830     


Measured dose response curve and IC50 of Talazoparib in W780 and W0069 cells.

29158830
Immunofluorescence
cleaved PARP / 53BP1; 

PubMed: 28958991     


Cleaved-PARP and 53BP1 expression. Representative images with 10× objective from high-content imaging of control cells in the left column, and cells treated with veliparib, olaparib, and talazoparib in three right columns. 53BP1 expression is seen in: A, HCC1143; B, MDAMB231; and C, HCC1806. Blue represents nuclear staining and pink foci represent 53BP1 foci. Cleaved-PARP expression is seen in D, HCC1143 and E, HCC1806. Blue represents nuclear staining and green represents cleaved-PARP expression.

RAD51; 

PubMed: 30621214     


(A) MCF7 and (B) MCF7-T cells were treated with either 100 nM tamoxifen (Tamox) or 1 nM talazoparib (Talaz) for 72 h, alone and in combination. 24 h post treatment RAD51 foci formation assay was performed. Scale bar: 20 µm.

28958991 30621214
In vivo In rat pharmacokinetic studies, BMN 673 displays >50% oralbioavailability and pharmacokinetic properties that enable singledaily dosing. In MX-1 xenograft tumor model studies, daily oral dosingof BMN 673 significantly enhances the antitumor effects ofcytotoxic therapies in a dose-dependent manner. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: MX-1 model (BRCA-1 deficient)
  • Dosages: 0.33 mg/kg/day, once daily
  • Administration: Oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL warmed (99.9 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 380.35
Formula

 

C19H14F2N6O
 
CAS No. 1207456-01-6
Storage powder
in solvent
Synonyms LT-673
Smiles CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04692662 Not yet recruiting Drug: talazoparib Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 8 2021 Phase 2
NCT04672460 Not yet recruiting Drug: TALZENNA capsule|Drug: Talazoparib soft gel capsule Advanced Solid Tumors Pfizer December 2020 Phase 1
NCT04497116 Recruiting Drug: RP-3500|Drug: Talazoparib: oral PARP inhibitor Advanced Solid Tumor Adult Repare Therapeutics July 22 2020 Phase 1|Phase 2
NCT04337970 Recruiting Drug: Talazoparib|Drug: Axitinib Kidney Cancer|Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma Memorial Sloan Kettering Cancer Center April 6 2020 Phase 1|Phase 2
NCT04134884 Recruiting Drug: Talazoparib|Drug: ASTX727 Metastatic Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Tumor Kathy Miller|Pfizer|Astex Pharmaceuticals Inc.|Van Andel Institute Stand Up to Cancer Team|Indiana University March 30 2020 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Which solvent do you recommend to dilute the inhibitor for in vivo study in mice?

  • Answer:

    BMN673 (S7048) can be dissolved in vehicle (10% DMAc, 6% Solutol, and 84% PBS) according to the paper: http://clincancerres.aacrjournals.org/content/19/18/5003.full. Quote from Method and Material section "Xenograft experiments: BMN 673 (various doses as indicated), or vehicle (10% DMAc, 6% Solutol, and 84% PBS) was administered by oral gavage"

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Talazoparib (BMN 673) | Talazoparib (BMN 673) supplier | purchase Talazoparib (BMN 673) | Talazoparib (BMN 673) cost | Talazoparib (BMN 673) manufacturer | order Talazoparib (BMN 673) | Talazoparib (BMN 673) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID